Activation of Nrf2, which is equal to the inhibition of Keap1, can be a pharmacological target in certain diseases linked with oxidative stress and inflammation, such as cancer, as well as metabolic, vascular, and neurodegenerative diseases. Here, NFE2L2 is linked to cancer.